Ribi Immunochem
Executive Summary
Will expand Phase II trial of melanoma tumor vaccine derived from cultured tumor cell lines and the firm's immunostimulant Detox from 70 patients to 270 patients at five new study sites. FDA clearance of the firm's Hamilton, Montana facility for the production of its cancer vaccine made the additional studies possible. The vaccine had been produced in limited amounts at the University of Southern California.